Tenth of Ramadan Company for Pharmaceutical Industries and Diagnostic Preparations - Rameda, has announced that it has notified the Egyptian Medicines Authority regarding the pricing of its new product, "Enviziram", which contains the active ingredient "faviravir", which was adopted as part of the virus treatment protocol (Covid-19), in Russia, China and India, where it was decided to launch the new drug at 1260 pounds per package, which contains 40 tablet
The company also obtained a notification from the Egyptian Medicines Authority regarding the pricing of its new product, "Remedisfer" ampoules for intravenous injection, which is to be used in the treatment of patients infected with Covid-19 virus, where it was decided to put the product under the brand (Remisdivir-Ramida) in the form of a dried rose intended for intravenous injection. At a price of 680 pounds for the ampoule, according to the company's statement to the Egyptian Stock Exchange, today, Tuesday.
Comments: 0
Post a Comment